<ul>
<li>啓動目標為 160 億美元的 SGLT-2 抑制劑市場，服務於美國 3300 萬名 2 型糖尿病患者，其中許多人沒有保險或保險不足，且自付費用超過 Brenzavvy 的現金價格</li>
<li>專有的 EinsteinRx™人工智能藥房平台使 Wellgistics 藥房網絡中的 6500 多家藥房能夠教育患者和提供者，瞭解 Brenzavvy 與 Jardiance®及其他 SGLT-2 抑制劑的優勢</li>
<li>降低患者的自付費用，併為藥劑師提供患者教育的收入機會，旨在支持 Brenzavvy 的更廣泛市場準入，並提升整體護理體驗</li>
<li>啓動建立了一種新模型，針對下一代改良藥物，提供與市場領導者相比的患者特定產品優勢</li>
</ul>
<p><strong>Wellgistics Health, Inc.（&#34;Wellgistics&#34;）（NASDAQ:WGRX）</strong>，一家健康信息技術領導者，將專有的藥房分發優化人工智能平台 <strong>EinsteinRx</strong> _<strong>™</strong>_整合到其專利的區塊鏈智能合約平台 <strong>PharmacyChain™</strong> 中，今天宣佈已開始在其 6500 家獨立藥房網絡（&#34;Wellgistics 藥房網絡&#34;）中商業推出糖尿病處方藥 Brenzavvy®，該網絡主要針對農村社區的患者，這些地區通常糖尿病發病率較高。此次推出的目標是 3300 萬名被診斷為 2 型糖尿病的美國人 [1]，他們的 SGLT-2 藥物自付費用超過 Brenzavvy 的現金價格。</p>
<p>Jardiance®和其他 SGLT-2 抑制劑藥物在 2024 年的銷售額達到 168 億美元，預計到 2033 年將增長至 289 億美元。根據 Grandview Research 的數據，美國佔該市場的 40.8%。對 2022-2023 年 28 個美國健康系統的數據進行的大規模分析顯示，糖尿病患者中推薦使用 SGLT-2 抑制劑的處方僅為 11.9%[3]，導致絕大多數患者的護理不理想。隨着公司的專有 <strong>EinsteinRx</strong> 人工智能藥房平台在 Wellgistics 藥房網絡的銷售點系統中推出，Wellgistics 將提醒藥劑師關注可能符合 SGLT-2 抑制劑 1A 類推薦的患者，以及在大多數沒有此類 1A 類推薦的情況下，使用 Brenzavvy 與其他 SGLT-2 抑制劑相比的潛在患者獲益。一旦被提醒，藥劑師將能夠迅速教育提供者，説明 Brenzavvy 與其他 SGLT-2 抑制劑在沒有心血管疾病或慢性腎病（CKD）患者中的優勢。Brenzavvy 與 Jardiance 及其他 SGLT-2 抑制劑的自付費用相比，具有競爭力的價格，為藥劑師主導的教育提供了有力的理由，以幫助優化處方決策並改善患者的獲取。</p>
<p>&#34;通過迅速幫助提供者優化患者的治療選擇，而不延遲藥物發放時間，藥劑師在幫助患者獲得更好結果方面處於獨特的位置，而無需增加自付費用，&#34;Wellgistics Health 的總裁兼臨時首席執行官 Prashant Patel，RPh 表示。&#34;藥劑師是關於處方藥如何影響患者健康的最可信的信息來源之一，尤其是在農村社區。<strong>EinsteinRx</strong> 正在賦能這些受信任的醫療專業人員，提供他們所需的先進技術，以便在正確的時間將正確的藥物提供給正確的患者。通過我們的 Wellgistics 藥房網絡推出 Brenzavvy，我們可以為產品和服務提供報酬機會，後者幫助藥劑師通過教育提供者瞭解 Brenzavvy 的患者特定優勢來提高投資回報率。我們相信，這種藥劑師主導的提供者教育模式將為其他具有類似產品優勢的後續藥物快速建立市場份額提供藍圖。&#34;</p>
<p><strong>關於 Wellgistics Health, Inc.</strong></p>
<p>Wellgistics Health（NASDAQ: WGRX）是一家健康信息技術領導者，將專有的藥房分發優化人工智能平台 EinsteinRx™整合到其專利的區塊鏈智能合約平台 PharmacyChain™中，以優化處方藥的發放過程。其集成平台連接 6500 多家藥房（&#34;Wellgistics 藥房網絡&#34;）和 200 多家制造商，提供批發分銷、數字處方路由、直接送藥到患者以及 AI 驅動的中心服務，如資格審核、依從性、入職、事先授權和現金支付履行等，以優化患者的獲取。Wellgistics 提供端到端解決方案，旨在恢復美國獨立藥房處方藥市場的獲取、透明度和信任。</p>
<p>欲瞭解更多信息，請訪問 www.wellgisticshealth.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據聯邦證券法的定義的前瞻性聲明，包括但不限於關於各方計劃談判最終協議、潛在實施、採用、表現、收入分享及其他預期利益的聲明。這些聲明面臨風險和不確定性，可能導致實際結果與預期結果有重大差異，包括在 DataVault AI, Inc.和 Wellgistics Health, Inc.向 SEC 提交的文件中所述的風險。前瞻性聲明僅在本日期有效，且兩家公司均不承擔更新這些聲明的義務，除非法律要求。其他因素在 Wellgistics Health 向 SEC 提交的文件中進行了討論，相關文件可在 www.sec.gov 獲取。</p>
<p>本新聞稿不構成在任何司法管轄區出售或招攬購買任何證券的要約，並且在任何此類要約、招攬或銷售違法的司法管轄區內將不進行證券的銷售。</p>
<p><strong>Wellgistics 媒體與投資者聯繫</strong></p>
<p>媒體：</p>
<p>media@wellgisticshealth.com</p>
<p>投資者關係：</p>
<p>IR@wellgisticshealth.com</p>
<p><strong>Wellgistics 投資者關係聯繫人</strong></p>
<p>Skyline Corporate Communications Group, LLC</p>
<p>Scott Powell, 總裁</p>
<p>1177 Avenue of the Americas, 5th Floor</p>
<p>New York, NY 10036</p>
<p>辦公室： (646) 893-5835</p>
<p>電子郵件： info@skylineccg.com</p>
<p>[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes</p>
<p>[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report</p>
<p>[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.</p>
<p><strong>來源：</strong> Wellgistics Health, Inc.</p>
<p>查看原始新聞稿請訪問 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNTM2NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNTM2NQ"/></p>

WGRX

<p>Wellgistics Health 推出了 Brenzavvy，這是一種針對 160 億美元 SGLT-2 抑制劑市場的糖尿病藥物。此次推出旨在降低美國 3300 萬名 2 型糖尿病患者的自付費用，利用 EinsteinRx 人工智能平台來教育藥劑師和醫療提供者。Brenzavvy 提供具有競爭力的定價和針對患者的優勢，增強市場準入和護理體驗。該倡議支持藥劑師主導的教育，以優化治療選擇，特別是在農村社區，並建立了一種重新配方藥物獲得市場份額的模式</p>

<ul>
<li>Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price</li>
<li>Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors</li>
<li>Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience</li>
<li>Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders</li>
</ul>
<div class="lb-trans"><ul>
<li>啓動目標為 160 億美元的 SGLT-2 抑制劑市場，服務於美國 3300 萬名 2 型糖尿病患者，其中許多人沒有保險或保險不足，且自付費用超過 Brenzavvy 的現金價格</li>
<li>專有的 EinsteinRx™人工智能藥房平台使 Wellgistics 藥房網絡中的 6500 多家藥房能夠教育患者和提供者，瞭解 Brenzavvy 與 Jardiance®及其他 SGLT-2 抑制劑的優勢</li>
<li>降低患者的自付費用，併為藥劑師提供患者教育的收入機會，旨在支持 Brenzavvy 的更廣泛市場準入，並提升整體護理體驗</li>
<li>啓動建立了一種新模型，針對下一代改良藥物，提供與市場領導者相比的患者特定產品優勢</li>
</ul>
</div><p><strong>Wellgistics Health, Inc. (&#34;Wellgistics&#34;) (NASDAQ:WGRX)</strong>, a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform <strong>EinsteinRx</strong> <em><strong>™</strong></em> into its patented blockchain-enabled smart contracts platform <strong>PharmacyChain™</strong>, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the &#34;Wellgistics Pharmacy Network&#34;) that primarily target patients in rural communities where there is often an increased incidence of diabetes. The launch is targeting the 33 million Americans who have been diagnosed with type II diabetes[1] and whose out-of-pocket costs for SGLT-2 drugs exceed the Brenzavvy cash price.</p>
<div class="lb-trans"><p><strong>Wellgistics Health, Inc.（&#34;Wellgistics&#34;）（NASDAQ:WGRX）</strong>，一家健康信息技術領導者，將專有的藥房分發優化人工智能平台 <strong>EinsteinRx</strong> _<strong>™</strong>_整合到其專利的區塊鏈智能合約平台 <strong>PharmacyChain™</strong> 中，今天宣佈已開始在其 6500 家獨立藥房網絡（&#34;Wellgistics 藥房網絡&#34;）中商業推出糖尿病處方藥 Brenzavvy®，該網絡主要針對農村社區的患者，這些地區通常糖尿病發病率較高。此次推出的目標是 3300 萬名被診斷為 2 型糖尿病的美國人 [1]，他們的 SGLT-2 藥物自付費用超過 Brenzavvy 的現金價格。</p>
</div><p>Jardiance® and other SGLT-2 inhibitor drugs reached sales of $16.8 billion in 2024, with projected growth projected to reach $28.9 billion by 2033. The United States represents 40.8% of that market according to Grandview Research[2]. A large scale analysis of data from 28 US health systems in 2022-2023 showed that guideline-recommended prescription of SGLT-2 inhibitors in diabetics with a class 1A recommendation is only 11.9%[3], leading to suboptimal care for the vast majority of such patients. As the Company's proprietary <strong>EinsteinRx</strong> artificial intelligence pharmacy platform is being rolled out into the Wellgistics Pharmacy Network's point-of-sales systems, Wellgistics will alert pharmacists to patients with a likely class 1A recommendation for a SGLT-2 inhibitor, as well as the likely patient benefit from dispensing Brenzavvy vs. other SGLT-2 inhibitors in the majority of cases where such a class 1A recommendation does not exist. Once alerted, pharmacists will be able to work to rapidly educate the provider on the benefits of Brenzavvy vs. other SGLT-2 inhibitors in patients without cardiovascular disease or chronic kidney disease (CKD). Brenzavvy's competitive price point when compared with the out-of-pocket costs of Jardiance &amp; other SGLT-2 inhibitors, provides a compelling rationale for pharmacist-driven education of providers to help optimize prescribing decisions and help improve patient access.</p>
<div class="lb-trans"><p>Jardiance®和其他 SGLT-2 抑制劑藥物在 2024 年的銷售額達到 168 億美元，預計到 2033 年將增長至 289 億美元。根據 Grandview Research 的數據，美國佔該市場的 40.8%。對 2022-2023 年 28 個美國健康系統的數據進行的大規模分析顯示，糖尿病患者中推薦使用 SGLT-2 抑制劑的處方僅為 11.9%[3]，導致絕大多數患者的護理不理想。隨着公司的專有 <strong>EinsteinRx</strong> 人工智能藥房平台在 Wellgistics 藥房網絡的銷售點系統中推出，Wellgistics 將提醒藥劑師關注可能符合 SGLT-2 抑制劑 1A 類推薦的患者，以及在大多數沒有此類 1A 類推薦的情況下，使用 Brenzavvy 與其他 SGLT-2 抑制劑相比的潛在患者獲益。一旦被提醒，藥劑師將能夠迅速教育提供者，説明 Brenzavvy 與其他 SGLT-2 抑制劑在沒有心血管疾病或慢性腎病（CKD）患者中的優勢。Brenzavvy 與 Jardiance 及其他 SGLT-2 抑制劑的自付費用相比，具有競爭力的價格，為藥劑師主導的教育提供了有力的理由，以幫助優化處方決策並改善患者的獲取。</p>
</div><p>&#34;By rapidly helping providers optimize therapy selection for patients without delaying dispensing timelines, pharmacists are uniquely positioned to help drive better outcomes for their patients without increasing out-of-pocket costs,&#34; said Prashant Patel, RPh, President &amp; Interim-CEO of Wellgistics Health. &#34;Pharmacists are one of the most trusted sources of information about how prescription drugs will impact the health of patients, especially in rural communities. <strong>EinsteinRx</strong> is empowering these trusted healthcare professionals with the advanced technology they need to get the right drug to the right patient at the right time. With the launch of Brenzavvy through our Wellgistics Pharmacy Network, we can provide remuneration opportunities for both products and services, with the latter helping pharmacists improve their ROI by educating providers on the patient-specific advantages of Brenzavvy. We believe that this pharmacist-led provider education model will enable the blueprint for other later-generation drugs with similar product profile advantages to rapidly establish market share.&#34;</p>
<div class="lb-trans"><p>&#34;通過迅速幫助提供者優化患者的治療選擇，而不延遲藥物發放時間，藥劑師在幫助患者獲得更好結果方面處於獨特的位置，而無需增加自付費用，&#34;Wellgistics Health 的總裁兼臨時首席執行官 Prashant Patel，RPh 表示。&#34;藥劑師是關於處方藥如何影響患者健康的最可信的信息來源之一，尤其是在農村社區。<strong>EinsteinRx</strong> 正在賦能這些受信任的醫療專業人員，提供他們所需的先進技術，以便在正確的時間將正確的藥物提供給正確的患者。通過我們的 Wellgistics 藥房網絡推出 Brenzavvy，我們可以為產品和服務提供報酬機會，後者幫助藥劑師通過教育提供者瞭解 Brenzavvy 的患者特定優勢來提高投資回報率。我們相信，這種藥劑師主導的提供者教育模式將為其他具有類似產品優勢的後續藥物快速建立市場份額提供藍圖。&#34;</p>
</div><p><strong>About Wellgistics Health, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Wellgistics Health, Inc.</strong></p>
</div><p>Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the &#34;Wellgistics Pharmacy Network&#34;) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.</p>
<div class="lb-trans"><p>Wellgistics Health（NASDAQ: WGRX）是一家健康信息技術領導者，將專有的藥房分發優化人工智能平台 EinsteinRx™整合到其專利的區塊鏈智能合約平台 PharmacyChain™中，以優化處方藥的發放過程。其集成平台連接 6500 多家藥房（&#34;Wellgistics 藥房網絡&#34;）和 200 多家制造商，提供批發分銷、數字處方路由、直接送藥到患者以及 AI 驅動的中心服務，如資格審核、依從性、入職、事先授權和現金支付履行等，以優化患者的獲取。Wellgistics 提供端到端解決方案，旨在恢復美國獨立藥房處方藥市場的獲取、透明度和信任。</p>
</div><p>For more information, visit www.wellgisticshealth.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.wellgisticshealth.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.</p>
<div class="lb-trans"><p>本新聞稿包含根據聯邦證券法的定義的前瞻性聲明，包括但不限於關於各方計劃談判最終協議、潛在實施、採用、表現、收入分享及其他預期利益的聲明。這些聲明面臨風險和不確定性，可能導致實際結果與預期結果有重大差異，包括在 DataVault AI, Inc.和 Wellgistics Health, Inc.向 SEC 提交的文件中所述的風險。前瞻性聲明僅在本日期有效，且兩家公司均不承擔更新這些聲明的義務，除非法律要求。其他因素在 Wellgistics Health 向 SEC 提交的文件中進行了討論，相關文件可在 www.sec.gov 獲取。</p>
</div><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.</p>
<div class="lb-trans"><p>本新聞稿不構成在任何司法管轄區出售或招攬購買任何證券的要約，並且在任何此類要約、招攬或銷售違法的司法管轄區內將不進行證券的銷售。</p>
</div><p><strong>Wellgistics Media &amp; Investor Contact</strong></p>
<div class="lb-trans"><p><strong>Wellgistics 媒體與投資者聯繫</strong></p>
</div><p>Media:</p>
<div class="lb-trans"><p>媒體：</p>
</div><p>media@wellgisticshealth.com</p>
<div class="lb-trans"><p>media@wellgisticshealth.com</p>
</div><p>Investor Relations:</p>
<div class="lb-trans"><p>投資者關係：</p>
</div><p>IR@wellgisticshealth.com</p>
<div class="lb-trans"><p>IR@wellgisticshealth.com</p>
</div><p><strong>Wellgistics Investor Relations Contact</strong></p>
<div class="lb-trans"><p><strong>Wellgistics 投資者關係聯繫人</strong></p>
</div><p>Skyline Corporate Communications Group, LLC</p>
<div class="lb-trans"><p>Skyline Corporate Communications Group, LLC</p>
</div><p>Scott Powell, President</p>
<div class="lb-trans"><p>Scott Powell, 總裁</p>
</div><p>1177 Avenue of the Americas, 5th Floor</p>
<div class="lb-trans"><p>1177 Avenue of the Americas, 5th Floor</p>
</div><p>New York, NY 10036</p>
<div class="lb-trans"><p>New York, NY 10036</p>
</div><p>Office: (646) 893-5835</p>
<div class="lb-trans"><p>辦公室： (646) 893-5835</p>
</div><p>Email: info@skylineccg.com</p>
<div class="lb-trans"><p>電子郵件： info@skylineccg.com</p>
</div><p>[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes</p>
<div class="lb-trans"><p>[1] https://my.clevelandclinic.org/health/diseases/21501-type-2-diabetes</p>
</div><p>[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report</p>
<div class="lb-trans"><p>[2] https://www.grandviewresearch.com/industry-analysis/sglt2-inhibitors-market-report</p>
</div><p>[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.</p>
<div class="lb-trans"><p>[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC11789666.</p>
</div><p><strong>SOURCE:</strong> Wellgistics Health, Inc.</p>
<div class="lb-trans"><p><strong>來源：</strong> Wellgistics Health, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新聞稿請訪問 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExNTM2NQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1115365"/></p>

Wellgistics Health 宣佈將糖尿病藥物 Brenzavvy(R) 推向 Wellgistics 藥房網絡 | WGRX 股票新聞